Cathay Biotech (SH:688065) Zheng Quan Zhi Xing·2025-08-15 14:10Core Viewpoint - The supervisory board of Shanghai Kasei Biotechnology Co., Ltd. held a meeting to review and approve the company's 2025 semi-annual report and related proposals, ensuring compliance with legal and regulatory requirements [1][2][3][4][5] Group 1: Supervisory Board Meeting - The meeting was convened on August 15, 2025, with all three members present, confirming the legality and validity of the resolutions made [1] - The supervisory board confirmed that the 2025 semi-annual report and its summary were prepared in accordance with relevant laws and internal regulations, ensuring the information disclosed is true, accurate, and complete [1][2] Group 2: Fund Management and Usage - The board approved the special report on the storage and usage of raised funds for the first half of 2025, confirming compliance with regulatory requirements and proper management of the funds [2][3] - The company ensured that the raised funds were stored in dedicated accounts and used for specified purposes, with no violations reported [2] Group 3: Stock Incentive Plans - The board approved the cancellation of unvested restricted stock from the 2020 incentive plan, confirming that the action complies with relevant laws and does not harm the interests of the company or its shareholders [3][4] - The board also approved an adjustment to the grant price of the 2022 restricted stock incentive plan from 56.45 yuan per share to 56.05 yuan per share, ensuring the adjustment followed legal procedures [4][5] - Additionally, the board approved the cancellation of unvested restricted stock from the 2022 incentive plan, affirming compliance with applicable regulations [5]